ANI Pharmaceuticals, Inc. (ANIP) Guidance & Earnings Results

On 2026-08-07 ANI Pharmaceuticals, Inc. reaffirmed guidance: "FY2026 total net revenue $1,080-1,140M; adjusted non-GAAP EBITDA $285-300M; Cortrophin Gel net revenue $520-540M (modestly adjusted from prior, reflecting 50-55%…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ANIPANI Pharmaceuticals, Inc.Follow ANIP — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 1.7B
P/E TTM: 15.7
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
7 Aug 26	Reaffirmed	FY2026 total net revenue $1,080-1,140M; adjusted non-GAAP EBITDA $285-300M; Cortrophin Gel net revenue $520-540M (modestly adjusted from prior, reflecting 50-55% growth) · full year
8 May 26	Raised	Revenue guidance raised to $1,080M-$1,140M; EBITDA to $285M-$300M; EPS to $9.19-$9.69 · full year
27 Feb 26	Raised	Expects to deliver more than $1 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue · full year
12 Jan 26	Raised	Preliminary 2026 guidance issued with revenue growth · full year
7 Nov 25	Raised	Revenue guidance raised to $854M-$873M; adjusted EBITDA to $221M-$228M; adjusted EPS to $7.37-$7.64 · full year
8 Aug 25	Raised	FY25 net revenues raised to $818M-$843M; adjusted EBITDA raised to $213M-$223M; adjusted EPS raised to $6.98-$7.35; Cortrophin Gel net revenues guided $322M-$329M; ILUVIEN/YUTIQ $87M-$93M. · full year

ANI Pharmaceuticals, Inc. — questions

What guidance did ANI Pharmaceuticals, Inc. give?: On 2026-08-07: "FY2026 total net revenue $1,080-1,140M; adjusted non-GAAP EBITDA $285-300M; Cortrophin Gel net revenue $520-540M (modestly adjusted from prior, reflecting 50-55% growth)"
When does ANI Pharmaceuticals, Inc. report earnings?: ANI Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-11.

Every figure on this page comes from ANI Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.